James D. Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James D. Allen has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Ted M. Ross
Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA; Department of Infectious Diseases, University of Georgia, Athens, GA, USA; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL, USA; Department of Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
8 shared publications - Giuseppe Andrea Sautto
Florida Research and Innovation Center, Cleveland Clinic
2 shared publications Hannah B. Hanley
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA
2 shared publicationsMatthew H. Thomas
Cleveland Clinic Florida Research and Innovation Center
2 shared publicationsMichael A. Carlock
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA
2 shared publicationsTed M. Ross
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA; Department of Infection Biology, Lehner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA
2 shared publications
Latest Publications
- Open Access
Computationally Optimized H1 and H3 Hemagglutinin Messenger RNA Vaccines Confer Broad Protective Immunity Against Modern Influenza Viruses
The hemagglutinin (HA) glycoprotein of seasonal influenza viruses undergoes continual antigenic drift, contributing to vaccine mismatch and reduced effectiveness of strain-specific seasonal vaccines. Although vaccination remains the most effective strategy for preventing influenza disease, conventional egg-based vaccine production requires several months and may not keep pace with viral evolution. Messenger RNA (mRNA) vaccines offer a promising alternative because they can be rapidly updated to encode emerging antigens and are manufactured through a scalable, cell-free process that avoids propagation associated adaptations. To address the challenges of antigenic drift and vaccine mismatch, we combined mRNA vaccine technology with Computationally Optimized Broadly Reactive Antigens (COBRA) to develop broadly protective influenza HA vaccines. These COBRA H1 and H3 mRNA HA vaccines elicited robust antigen-specific IgG, hemagglutination inhibition (HAI), and neutralizing antibody responses against diverse historical and contemporary influenza strains in cohorts of influenza naĂŻve and pre-immune mice. Vaccination also induced strong cellular immunity, characterized by the expansion of antigen-specific antibody and cytokine secreting cells. These responses were further enhanced in animals with pre-existing influenza immunity, as demonstrated by an increased frequency of IFN-Îł producing cells recognizing conserved HA stalk-based peptides. Together, these findings demonstrate that COBRA HA encoding mRNA vaccines can effectively leverage immunological memory while expanding responses to conserved HA epitopes, supporting improved protection against antigenically drifted strains. Thus, the combination of broadly reactive COBRA HA antigens with a rapidly adaptable and manufacturable mRNA platform represents a promising strategy for next-generation influenza vaccination.
Open AccessComputationally Optimized H1 and H3 Hemagglutinin Messenger RNA Vaccines Confer Broad Protective Immunity Against Modern Influenza Viruses
The hemagglutinin (HA) glycoprotein of seasonal influenza viruses undergoes continual antigenic drift, contributing to vaccine mismatch and reduced effectiveness of strain-specific seasonal vaccines. Although vaccination remains the most effective strategy for preventing influenza disease, conventional egg-based vaccine production requires several months and may not keep pace with viral evolution. Messenger RNA (mRNA) vaccines offer a promising alternative because they can be rapidly updated to encode emerging antigens and are manufactured through a scalable, cell-free process that avoids propagation associated adaptations. To address the challenges of antigenic drift and vaccine mismatch, we combined mRNA vaccine technology with Computationally Optimized Broadly Reactive Antigens (COBRA) to develop broadly protective influenza HA vaccines. These COBRA H1 and H3 mRNA HA vaccines elicited robust antigen-specific IgG, hemagglutination inhibition (HAI), and neutralizing antibody responses against diverse historical and contemporary influenza strains in cohorts of influenza naĂŻve and pre-immune mice. Vaccination also induced strong cellular immunity, characterized by the expansion of antigen-specific antibody and cytokine secreting cells. These responses were further enhanced in animals with pre-existing influenza immunity, as demonstrated by an increased frequency of IFN-Îł producing cells recognizing conserved HA stalk-based peptides. Together, these findings demonstrate that COBRA HA encoding mRNA vaccines can effectively leverage immunological memory while expanding responses to conserved HA epitopes, supporting improved protection against antigenically drifted strains. Thus, the combination of broadly reactive COBRA HA antigens with a rapidly adaptable and manufacturable mRNA platform represents a promising strategy for next-generation influenza vaccination.
- Open Access
Design and characterization of broadly protective influenza A(H3N2) vaccine candidates using protein language models
Seasonal influenza A viruses cause significant global morbidity each year. Although vaccination remains the primary preventive strategy, effectiveness is often reduced by antigenic drift. This challenge is particularly pronounced for influenza A(H3N2), which has required eight vaccine updates over the past decade. Here, we present a computational framework to engineer broadly reactive influenza A(H3N2) vaccines, using protein language models to generate novel hemagglutinin (HA) sequences and a machine learning model to predict antigenic distance from circulating strains. In a proof-of-concept study, seven HA candidates designed using sequence data from 2013–2018 were evaluated in mice against contemporary and subsequently circulating viruses. Two candidates elicited protective levels of reactive antibodies, robust H3-specific antibody-secreting cell responses, and cross-neutralization against contemporary clades and drifted 2019-2020 strains. These findings demonstrate that an integrated generation–selection strategy can enhance vaccine coverage across current and future A(H3N2) seasons and may be applicable to other influenza subtypes.
Open AccessDesign and characterization of broadly protective influenza A(H3N2) vaccine candidates using protein language models
Seasonal influenza A viruses cause significant global morbidity each year. Although vaccination remains the primary preventive strategy, effectiveness is often reduced by antigenic drift. This challenge is particularly pronounced for influenza A(H3N2), which has required eight vaccine updates over the past decade. Here, we present a computational framework to engineer broadly reactive influenza A(H3N2) vaccines, using protein language models to generate novel hemagglutinin (HA) sequences and a machine learning model to predict antigenic distance from circulating strains. In a proof-of-concept study, seven HA candidates designed using sequence data from 2013–2018 were evaluated in mice against contemporary and subsequently circulating viruses. Two candidates elicited protective levels of reactive antibodies, robust H3-specific antibody-secreting cell responses, and cross-neutralization against contemporary clades and drifted 2019-2020 strains. These findings demonstrate that an integrated generation–selection strategy can enhance vaccine coverage across current and future A(H3N2) seasons and may be applicable to other influenza subtypes.
- 20 June 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233  (1) , 122-131
Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: A Secondary Analysis of an Animal Challenge Trial
Background: Hemagglutination inhibition (HAI) titers are key correlates of influenza vaccine protection, yet a systematic comparison of HAI-based immunogenicity indicators is lacking for guiding vaccine development. This study aimed to compare these indicators by evaluating their correlation with influenza disease outcomes. Method: We performed a secondary analysis of a mouse challenge study, in which 14 groups of mice were first challenged and received different H3N2 vaccines and were subsequently infected with H3N2 (A/Kansas/14/2017). Disease outcomes were measured by weight loss and lung viral load. HAI titers were assessed against 9 H3N2 strains, including the infecting strain, vaccine strains, and others, generating 11 HAI-based indicators considering that the HAI titer was against the vaccine strains, the infecting strain, and the similarity between strains based on 2 antigenic distance algorithms. Correlations with disease outcomes were evaluated using linear regression models, with R2 values and bootstrap resampling estimating variance. Results: HAI titers against vaccine strains showed the weakest correlation with disease outcomes due to strain mismatch. The proportion of seroprotection among the 9 strains demonstrated the strongest correlation, with R2 values of approximately 0.4 (weight loss) and approximately 0.6 (lung viral load). Indicators based on antigenic distance were also predictive but not superior. Conclusions: Relying solely on HAI titers against a single virus is insufficient for assessing influenza vaccine effectiveness. Calculating the proportion of seroprotection, a computationally efficient metric, offers robust predictive power and may be superior to traditional single-strain titer even when it matches the infecting strain.
- 20 June 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233  (1) , 122-131
Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: A Secondary Analysis of an Animal Challenge Trial
Background: Hemagglutination inhibition (HAI) titers are key correlates of influenza vaccine protection, yet a systematic comparison of HAI-based immunogenicity indicators is lacking for guiding vaccine development. This study aimed to compare these indicators by evaluating their correlation with influenza disease outcomes. Method: We performed a secondary analysis of a mouse challenge study, in which 14 groups of mice were first challenged and received different H3N2 vaccines and were subsequently infected with H3N2 (A/Kansas/14/2017). Disease outcomes were measured by weight loss and lung viral load. HAI titers were assessed against 9 H3N2 strains, including the infecting strain, vaccine strains, and others, generating 11 HAI-based indicators considering that the HAI titer was against the vaccine strains, the infecting strain, and the similarity between strains based on 2 antigenic distance algorithms. Correlations with disease outcomes were evaluated using linear regression models, with R2 values and bootstrap resampling estimating variance. Results: HAI titers against vaccine strains showed the weakest correlation with disease outcomes due to strain mismatch. The proportion of seroprotection among the 9 strains demonstrated the strongest correlation, with R2 values of approximately 0.4 (weight loss) and approximately 0.6 (lung viral load). Indicators based on antigenic distance were also predictive but not superior. Conclusions: Relying solely on HAI titers against a single virus is insufficient for assessing influenza vaccine effectiveness. Calculating the proportion of seroprotection, a computationally efficient metric, offers robust predictive power and may be superior to traditional single-strain titer even when it matches the infecting strain.
- Open Access
- 26 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 116, 105744
Leveraging pre-vaccination antibody titres across multiple influenza H3N2 variants to forecast the post-vaccination response
- 26 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 116, 105744
Open AccessLeveraging pre-vaccination antibody titres across multiple influenza H3N2 variants to forecast the post-vaccination response
- Open Access
Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune® Generate Broadly Protective Antibody Responses in Mice and Ferrets
Background/Objectives: Standard-of-care influenza vaccines contain antigens that are typically derived from components of wild type (WT) influenza viruses. Often, these antigens elicit strain-specific immune responses and are susceptible to mismatch in seasons where antigenic drift is prevalent. Thanks to advances in viral surveillance and sequencing, influenza vaccine antigens can now be optimized using computationally derived methodologies and algorithms to enhance their immunogenicity. Methods: Mice and ferrets that had been previously exposed to historical H1N1 and H3N2 influenza viruses were vaccinated intramuscularly with bivalent mixtures of H1 and H3 recombinant hemagglutinin (rHA) proteins, which were generated using a computationally optimized broadly reactive antigen (COBRA) design methodology. The vaccine antigens were mixed with a cationic lipid nanoparticle adjuvant, Infectimune®, which promotes both humoral and cellular immune responses. Results: Mice and ferrets vaccinated with Infectimune® and COBRA rHAs elicited protective antibody titers against panels of H1N1 and H3N2 influenza viruses isolated over the past 10 years. These animals also had antibodies that neutralized numerous modern H1N1 and H3N2 influenza viruses in vitro. When challenged with the A/Victoria/2570/2019 H1N1 influenza virus, the COBRA rHA vaccinated animals had minimal weight loss, and no detectable virus was present in their respiratory tissues on day 3 post-infection. Conclusions: These results demonstrate that COBRA rHA vaccines formulated with Infectimune® elicit protective antibody responses against influenza strains, which were isolated across periods of time when standard-of-care vaccines were frequently reformulated, thus reducing the need to update vaccines on a nearly annual basis.
Open AccessComputationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune® Generate Broadly Protective Antibody Responses in Mice and Ferrets
Background/Objectives: Standard-of-care influenza vaccines contain antigens that are typically derived from components of wild type (WT) influenza viruses. Often, these antigens elicit strain-specific immune responses and are susceptible to mismatch in seasons where antigenic drift is prevalent. Thanks to advances in viral surveillance and sequencing, influenza vaccine antigens can now be optimized using computationally derived methodologies and algorithms to enhance their immunogenicity. Methods: Mice and ferrets that had been previously exposed to historical H1N1 and H3N2 influenza viruses were vaccinated intramuscularly with bivalent mixtures of H1 and H3 recombinant hemagglutinin (rHA) proteins, which were generated using a computationally optimized broadly reactive antigen (COBRA) design methodology. The vaccine antigens were mixed with a cationic lipid nanoparticle adjuvant, Infectimune®, which promotes both humoral and cellular immune responses. Results: Mice and ferrets vaccinated with Infectimune® and COBRA rHAs elicited protective antibody titers against panels of H1N1 and H3N2 influenza viruses isolated over the past 10 years. These animals also had antibodies that neutralized numerous modern H1N1 and H3N2 influenza viruses in vitro. When challenged with the A/Victoria/2570/2019 H1N1 influenza virus, the COBRA rHA vaccinated animals had minimal weight loss, and no detectable virus was present in their respiratory tissues on day 3 post-infection. Conclusions: These results demonstrate that COBRA rHA vaccines formulated with Infectimune® elicit protective antibody responses against influenza strains, which were isolated across periods of time when standard-of-care vaccines were frequently reformulated, thus reducing the need to update vaccines on a nearly annual basis.
- Open Access
- 25 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19  (6) , e0301157
Longitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons
Participants between the ages of 10–86 years old were vaccinated with split-inactivated influenza vaccine (Fluzone®) in six consecutive influenza seasons from 2016–2017 to 2021–2022. Vaccine effectiveness varies from season to season as a result of both host immune responses as well as evolutionary changes in the influenza virus surface glycoproteins that provide challenges to vaccine manufacturers to produce more effective annual vaccines. Next generation influenza vaccines are in development and may provide protective immune responses against a broader number of influenza viruses and reduce the need for annual vaccination. An improved understanding how current influenza vaccines are influenced by human host immune responses in people of different ages and co-morbidities is necessary for designing the next-generation of ’universal’ or broadly-protective influenza vaccines. Overall, pre-existing immune responses to previous influenza virus exposures, either by past infections or vaccinations, is a critical factor influencing host responses to seasonal influenza vaccination. Participants vaccinated in consecutive seasons had reduced serum hemagglutination-inhibition (HAI) activity against strains included in the vaccine compared to participants that had not been vaccinated in the preceding 1–2 years prior to entering this study. The magnitude and breadth of these antibody responses were also modulated by the age of the participant. Elderly participants over 65 years of age, in general, had lower pre-existing HAI titers each season prior to vaccination with lower post-vaccination titers compared to children or young adults under the age of 35. The administration of higher doses (HD) of the split-inactivated vaccine enhanced the antibody titers in the elderly. This report showcases 6 consecutive years of antibody HAI activity in human subjects receiving seasonal split-inactivated influenza vaccine.
- 25 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19  (6) , e0301157
Open AccessLongitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons
Participants between the ages of 10–86 years old were vaccinated with split-inactivated influenza vaccine (Fluzone®) in six consecutive influenza seasons from 2016–2017 to 2021–2022. Vaccine effectiveness varies from season to season as a result of both host immune responses as well as evolutionary changes in the influenza virus surface glycoproteins that provide challenges to vaccine manufacturers to produce more effective annual vaccines. Next generation influenza vaccines are in development and may provide protective immune responses against a broader number of influenza viruses and reduce the need for annual vaccination. An improved understanding how current influenza vaccines are influenced by human host immune responses in people of different ages and co-morbidities is necessary for designing the next-generation of ’universal’ or broadly-protective influenza vaccines. Overall, pre-existing immune responses to previous influenza virus exposures, either by past infections or vaccinations, is a critical factor influencing host responses to seasonal influenza vaccination. Participants vaccinated in consecutive seasons had reduced serum hemagglutination-inhibition (HAI) activity against strains included in the vaccine compared to participants that had not been vaccinated in the preceding 1–2 years prior to entering this study. The magnitude and breadth of these antibody responses were also modulated by the age of the participant. Elderly participants over 65 years of age, in general, had lower pre-existing HAI titers each season prior to vaccination with lower post-vaccination titers compared to children or young adults under the age of 35. The administration of higher doses (HD) of the split-inactivated vaccine enhanced the antibody titers in the elderly. This report showcases 6 consecutive years of antibody HAI activity in human subjects receiving seasonal split-inactivated influenza vaccine.
- 13 April 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96  (7) , e0165221
Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019
Standard-of-care influenza virus vaccines are composed of a mixture of antigens from different influenza viral subtypes. For the first time, lead COBRA H1 and H3 HA antigens, formulated as a bivalent vaccine, have been investigated in animals with preexisting immunity to influenza viruses.
- 13 April 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96  (7) , e0165221
Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019
Standard-of-care influenza virus vaccines are composed of a mixture of antigens from different influenza viral subtypes. For the first time, lead COBRA H1 and H3 HA antigens, formulated as a bivalent vaccine, have been investigated in animals with preexisting immunity to influenza viruses.
- Top Cited Papers
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- Open Access
- 28 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13  (9) , e0204284
Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses
Development of broadly reactive or universal influenza vaccines will be a paradigm shifting event for the influenza vaccine field. These next generation vaccines could replace the current standard of care with vaccines that elicit broadly cross-protective immune responses. However, a variety of in vitro and in vivo models are necessary to make the best assessments of these vaccine formulations to determine their mechanisms of action, and allow for downselection of candidates prior to human clinical trials. Our group has developed the computationally optimized broadly reactive antigen (COBRA) technology to develop HA head-based strategies to elicit antibodies against H1, H3, and H5 influenza strains. These vaccines elicit broadly reactive antibody responses that neutralize not only historical and contemporary vaccine strains, but also co-circulating variants in mice. In this study, we used H1 and H3 HA antigens in a split, inactivated vaccine (IIV) formulation in combination with the AF03 squalene-in-water emulsion adjuvant in ferrets immunologically naĂŻve to influenza virus. The H3 COBRA IIV vaccine T11 elicited antibodies with HAI activity against more H3N2 influenza strains compared to IIV expressing wild-type H3 HA antigens, except for IIV vaccines expressing the HA from A/Texas/50/2012 (Tx/12) virus. H1 COBRA IIV vaccines, P1 and X6, elicited antibodies that recognized a similar number of H1N1 viruses as those antibodies elicited by IIV expressing the A/California/07/2009 (CA/09) HA. Ferrets vaccinated with the P1 or X6 COBRA IIV were protected against CA/09 challege and cleared virus from the lungs of the ferrets, similar to ferrets vaccinated with the CA/09 IIV.
- 28 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13  (9) , e0204284
Open AccessSplit inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses
Development of broadly reactive or universal influenza vaccines will be a paradigm shifting event for the influenza vaccine field. These next generation vaccines could replace the current standard of care with vaccines that elicit broadly cross-protective immune responses. However, a variety of in vitro and in vivo models are necessary to make the best assessments of these vaccine formulations to determine their mechanisms of action, and allow for downselection of candidates prior to human clinical trials. Our group has developed the computationally optimized broadly reactive antigen (COBRA) technology to develop HA head-based strategies to elicit antibodies against H1, H3, and H5 influenza strains. These vaccines elicit broadly reactive antibody responses that neutralize not only historical and contemporary vaccine strains, but also co-circulating variants in mice. In this study, we used H1 and H3 HA antigens in a split, inactivated vaccine (IIV) formulation in combination with the AF03 squalene-in-water emulsion adjuvant in ferrets immunologically naĂŻve to influenza virus. The H3 COBRA IIV vaccine T11 elicited antibodies with HAI activity against more H3N2 influenza strains compared to IIV expressing wild-type H3 HA antigens, except for IIV vaccines expressing the HA from A/Texas/50/2012 (Tx/12) virus. H1 COBRA IIV vaccines, P1 and X6, elicited antibodies that recognized a similar number of H1N1 viruses as those antibodies elicited by IIV expressing the A/California/07/2009 (CA/09) HA. Ferrets vaccinated with the P1 or X6 COBRA IIV were protected against CA/09 challege and cleared virus from the lungs of the ferrets, similar to ferrets vaccinated with the CA/09 IIV.
- 1 December 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 199  (11) , 3798-3807
Infection of Ferrets with Influenza Virus Elicits a Light Chain–Biased Antibody Response against Hemagglutinin
The domestic ferret (Mustela putorius furo) is a commonly used animal model for the study of influenza virus infection and vaccination. Recently, our group has developed murine mAbs with specificity for the κ (Igκ) and λ (Igλ) L chains of ferret Ig. These mAbs were used to quantify the abundance of Igκ and Igλ in serum and to evaluate L chain usage of the Ab response against the hemagglutinin (HA) protein elicited by influenza infection. After influenza A infection of immunologically naive ferrets with various H1N1 or H3N2 strains, the acute Ab response against HA exhibited an inherent bias toward λ L chain usage. In contrast, secondary infection of H1N1 preimmune ferrets with an antigenically distinct H1N1 virus elicited a recall response against the original HA that was no longer biased toward Igλ and possessed differential specificity. Moreover, sequential infection of ferrets with H1N1 influenza viruses elicited an Igκ-biased Ab response directed against the HA globular head and stem regions. Furthermore, sequential infection of ferrets with viral vectors expressing chimeric HA, aimed at boosting Ab reactivity against the HA stem region, also elicited an Igκ-biased response. Collectively, these findings suggest that ferret B cells expressing an Igκ or Igλ BCR possess differential specificities, and highlight the utility of our recently developed mAbs for studying the immune response to influenza virus infection and vaccination in the ferret model.
- 1 December 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 199  (11) , 3798-3807
Infection of Ferrets with Influenza Virus Elicits a Light Chain–Biased Antibody Response against Hemagglutinin
The domestic ferret (Mustela putorius furo) is a commonly used animal model for the study of influenza virus infection and vaccination. Recently, our group has developed murine mAbs with specificity for the κ (Igκ) and λ (Igλ) L chains of ferret Ig. These mAbs were used to quantify the abundance of Igκ and Igλ in serum and to evaluate L chain usage of the Ab response against the hemagglutinin (HA) protein elicited by influenza infection. After influenza A infection of immunologically naive ferrets with various H1N1 or H3N2 strains, the acute Ab response against HA exhibited an inherent bias toward λ L chain usage. In contrast, secondary infection of H1N1 preimmune ferrets with an antigenically distinct H1N1 virus elicited a recall response against the original HA that was no longer biased toward Igλ and possessed differential specificity. Moreover, sequential infection of ferrets with H1N1 influenza viruses elicited an Igκ-biased Ab response directed against the HA globular head and stem regions. Furthermore, sequential infection of ferrets with viral vectors expressing chimeric HA, aimed at boosting Ab reactivity against the HA stem region, also elicited an Igκ-biased response. Collectively, these findings suggest that ferret B cells expressing an Igκ or Igλ BCR possess differential specificities, and highlight the utility of our recently developed mAbs for studying the immune response to influenza virus infection and vaccination in the ferret model.